NY-IWBI
26.3.2020 09:02:26 CET | Business Wire | Press release
The International WELL Building Institute (IWBI) announced today that it is standing up a Task Force on reducing the enormous health burden from COVID-19 and other respiratory infections. Its goal is to define the critical role buildings, organizations and communities play in prevention and preparedness, resilience and recovery. The Task Force's work will take a broad approach, considering both new and recurring infectious agents that can affect large populations.
Co-chairing the Task Force are Risa Lavizzo-Mourey, M.D., MBA , former president and CEO of the Robert Wood Johnson Foundation and distinguished professor of population health and health equity at the University of Pennsylvania; Jonathan Fielding, M.D., MPH, MA, MBA , distinguished professor at UCLA in the Fielding School of Public Health and the Geffen School of Medicine and former director and health officer of the Los Angeles County Department of Public Health; Richard Carmona, M.D., MPH, FACS , who was 17th Surgeon General of the United States and is presently distinguished professor at the University of Arizona; and Joseph Allen, DSc, MPH, assistant professor and director of the Healthy Buildings program at Harvard’s T.H. Chan School of Public Health. The task force will include experts from public health, government, academia and philanthropy, as well as the architecture, design and real estate communities.
“IWBI’s work centers on providing evidence-backed solutions that advance better health and well-being in the places and spaces where we spend our lives,” said IWBI Chairman and CEO Rick Fedrizzi. “The creation of this Task Force provides a mechanism to focus on this immediate challenge and collect and apply the expertise and insight of our global community, which includes practicing physicians, environmental and behavioral scientists, leading design practitioners and innovation leaders from global corporations.”
“This task force can help us focus quickly on actionable measures we can take to more fully deliver resources needed to advance a global culture of health that includes everyone,” said Dr. Lavizzo-Mourey.
“This timely effort will mine the scientific literature to identify enhanced opportunities for the built environment to improve population health,” said Dr. Fielding.
Surgeon General Carmona commends IWBI for bringing together global public health thought leaders to focus on optimizing the built environment to prevent, respond to, mitigate and recover from “all hazards” to the United States to include coronavirus. The built environment is an essential element in physical and mental health as well as preventing disease.
“The urgency of action towards mitigating the physical, emotional and economic impacts of this virus and other respiratory infections cannot be overstated,” said Dr. Allen. “Nor can the outsized impact that can occur if we improve our buildings, as well as the policies, protocols and procurement guidelines organizations have in place, so that they work together to protect and improve the health of everyone. This pandemic is the challenge of our time and buildings will play a central role in our response, and ultimate recovery.“
“The aim of the Task Force is twofold,” said IWBI President Rachel Gutter. “First, to identify and develop a set of signature deliverables and resources, including guidelines for individuals, organizations and communities to help them better integrate actionable insights and proven strategies into how they manage both their buildings and their organizations. Second, the Task Force will assess ways in which the WELL Building Standard (WELL) itself can be further strengthened so the system, which touches more than a half-billion square feet of space across 58 countries, can best continue to support prevention and preparedness, resiliency and recovery in this critical moment and into the future.”
Gutter noted that more information about the Task Force and how individuals can raise their hands to get involved can be found here .
“WELL already reflects the massive amount of current health research and data we’ve amassed and integrated since its launch in late 2014,” she said. “But the landscape shifted at the first of the year with the global onset of this virus. We are committed to making sure we share freely everything we’ve learned with our global community and beyond. We owe it to everyone to make sure the comprehensive, evidence-based interventions that we’ve codified in WELL move us in the direction of better health and enhanced resilience for everyone, everywhere.”
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here
.
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005121/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
